Abstract
Recent data suggest that SRC family kinases (SFKs) could represent potential therapeutic targets for rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children. Here, we assessed the effect of a recently developed selective SFK inhibitor (a pyrazolo[3,4-d]pyrimidine derivative, called SI221) on RMS cell lines. SI221, which showed to be mainly effective against the SFK member YES, significantly reduced cell viability and induced apoptosis, without affecting non-tumor cells, such as primary human skin fibroblasts and differentiated C2C12 cells. Moreover, SI221 decreased in vitro cell migration and invasion and reduced tumor growth in a RMS xenograft model. SFK inhibition also induced muscle differentiation in RMS cells by affecting the NOTCH3 receptor-p38 mitogen-activated protein kinase (MAPK) axis, which regulates the balance between proliferation and differentiation. Overall, our findings suggest that SFK inhibition, besides reducing RMS cell growth and invasive potential, could also represent a differentiation therapeutic strategy for RMS.
References
Dec 1, 1982·The Journal of Cell Biology·D BaderD A Fischman
Feb 26, 1993·Cell·D N LevyD B Weiner
Sep 28, 1999·Oncogene·G Merlino, L J Helman
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Apr 28, 2004·Bioorganic & Medicinal Chemistry Letters·S SchenoneM Botta
Jun 2, 2004·Nature Reviews. Cancer·Timothy J Yeatman
Mar 1, 2006·BMC Bioinformatics·Joshua S YuanC Neal Stewart
Mar 3, 2006·Journal of Medicinal Chemistry·Fabio CarraroMaurizio Botta
Apr 18, 2006·Cell Research·Patrizia BossolascoLorenza Lazzari
Aug 3, 2006·The Journal of Biological Chemistry·Patrick LaplanteMarie-Josée Hébert
Dec 13, 2006·The Journal of Biological Chemistry·Kunio KondohEisuke Nishida
Feb 17, 2007·The EMBO Journal·Eusebio PerdigueroPura Muñoz-Cánoves
Feb 22, 2007·Oncogene·H LueJ Bernhagen
Mar 17, 2007·Cancer Research·Audrey C ShorRichard Jove
Jul 7, 2007·Archives of Biochemistry and Biophysics·Min Jin LimSung Soo Kim
Jan 4, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Adriano SpreaficoAnnalisa Santucci
Sep 1, 2009·BMC Cancer·Valentina MasolaMaurizio Onisto
Nov 12, 2009·Future Oncology·Carla De GiovanniPatrizia Nanni
Jun 19, 2010·Expert Opinion on Investigational Drugs·Silvia SchenoneMaurizio Botta
Aug 10, 2010·Transplantation Proceedings·E PianigianiM Fimiani
Dec 24, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Josep RomaSoledad Gallego
Jul 23, 2011·Genes & Cancer·Ulrica TostarTakashi Shimokawa
Jul 26, 2011·Oncogene·P IndovinaF Pentimalli
Sep 16, 2011·Journal of Dental Research·C Wang
Sep 29, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian C BelyeaCorinne M Linardic
Nov 4, 2011·Nature Cell Biology·Primal de Lanerolle, Leonid Serebryannyy
Nov 26, 2011·Cell Death and Differentiation·L RaimondiR Rota
Feb 16, 2012·Cell Cycle·Martina CozziPaola Indovina
Apr 6, 2012·PloS One·Yong-Chao MaZe-Sheng Wang
May 9, 2012·Mayo Clinic Proceedings·Carola A S ArndtNadia N Laack
Jul 14, 2012·PloS One·Hiroko NagaoSetsuro Komiya
Jan 16, 2013·Oncogene·C L YeungL J Helman
Jun 12, 2013·Journal of Medicinal Chemistry·Marco RadiMaurizio Botta
Citations
Apr 5, 2017·Annual Review of Analytical Chemistry·Xiaowen YuSylvia Daunert
Jul 16, 2020·Cancers·Paola IndovinaAntonio Giordano
Feb 24, 2016·Scientific Reports·Giulia VignaroliMaurizio Botta
Jun 30, 2019·Cancers·Anna Lucia FallacaraSilvia Schenone
Jun 18, 2020·Cancers·Marija NešovićJelena Dinić
Jun 22, 2016·Oncotarget·Huili LiJiliang Wang
Sep 10, 2017·Pathology Oncology Research : POR·Karina UeharaTakao Kinjo
Apr 3, 2016·Journal of Cellular Physiology·Paola IndovinaAntonio Giordano
Jul 3, 2018·Oncology Letters·Shutong DuFeng Li
Feb 22, 2021·Cancer Letters·Silvia CodenottiAlessandro Fanzani
Jul 24, 2018·ACS Medicinal Chemistry Letters·Pierpaolo CalandroArianna Mancini
Mar 16, 2018·ACS Medicinal Chemistry Letters·Monica SannaCameron Alexander